What should be done for immune thrombocytopenia?
Aug 18, 2021
Source: Cainiu Health
Dr. Xing Jian
Introduction
What to do about immune thrombocytopenia (ITP): Treatment is primarily individualized based on the patient’s specific clinical situation. Generally, if the platelet count falls below 20 × 10⁹/L, bed rest is recommended, along with avoidance of trauma and administration of hemostatic agents. Close observation is warranted to assess for any signs or symptoms of bleeding. In patients without active bleeding, no planned surgical procedures, and no high-risk occupations (i.e., those posing a significant risk of injury), the risk of bleeding is relatively low; thus, observation without pharmacologic intervention may be appropriate.
Immune thrombocytopenia (ITP), formerly known as idiopathic thrombocytopenic purpura, is a complex, acquired autoimmune disorder involving multiple pathogenic mechanisms. Management is individualized based on clinical circumstances. Generally, if the platelet count falls below 20 × 109/L, patients should remain on bed rest, avoid trauma, and receive hemostatic agents; close observation is warranted to assess for signs of bleeding.
In contrast, patients with baseline platelet counts above 30 × 109/L who are not scheduled for surgery or invasive procedures—and who do not engage in occupations or activities associated with an elevated risk of bleeding—have a relatively low risk of hemorrhage and may be managed with observation alone, without pharmacologic intervention.For newly diagnosed ITP, first-line treatment is corticosteroids, which achieve response rates of approximately 80%. In emergency situations requiring rapid platelet count elevation, intravenous immunoglobulin (IVIG) may be administered at either 400 mg/kg/day for at least five consecutive days or 1 g/kg/day for two days.
Second-line therapies are indicated when standard corticosteroid treatment fails. These include anti-CD20 monoclonal antibodies, thrombopoietin (TPO) receptor agonists, and splenectomy.
